Top Markets
Coin of the day
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
株式のランク #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
株価
$0.30780727
時価総額
$94.19M
変化(1日)
-0.19%
変化(1年)
-34.73%
FR
取引 Sensorion SA (ALSEN)

カテゴリー

Sensorion SA(ALSEN)の発行済株式数
December 2025 時点の発行済株式数 300.92M
Sensorion SA の最新の財務報告および株価によると、現在の発行済株式数は 300.92M です。December 2023 の終わりには、同社は 133.42M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Sensorion SA(ALSEN)の発行済株式数の履歴(2011 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
2026 (TTM) 300.92M 5.97%
2024 283.97M 112.83%
2023 133.42M 67.12%
2022 79.84M 0.18%
2021 79.69M 31.16%
2020 60.76M 225.81%
2019 18.65M 63.39%
2018 11.41M 58.34%
2017 7.21M 5.84%
2016 6.81M 59.47%
2015 4.27M 30.90%
2014 3.26M 0.00%
2013 3.26M 0.00%
2012 3.26M 0.00%
2011 3.26M 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数
4.44B 1,376.33%
DK
254.10M -15.56%
US
104.00M -65.44%
US
190.00M -36.86%
BE
61.42M -79.59%
NL